May 10, 2013
Shareholder rights law
firm Robbins Arroyo LLP is investigating whether officers and directors of Chemed Corporation (NYSE: CHE) breached their fiduciary duties to shareholders. Chemed, through its subsidiaries, provides hospice services to patients in
the United States
The U.S. Department of Justice Files False Claims Act Lawsuit Against Chemed
May 2, 2013
, U.S. Department of Justice ("DOJ") announced that it filed a lawsuit against Chemed, and several of its wholly owned hospice subsidiaries, alleging that the company falsely billed Medicaid tens of millions of dollars for crisis care hospice services costing taxpayers tens of millions of dollars. Crisis care is available to patients with acute medical symptoms requiring immediate short-term care, and is billed at the highest daily rate a hospice can bill Medicare.
Specifically, the lawsuit alleges that the company submitted false claims for crisis services that were not necessary, not performed, or not performed in accordance with Medicare requirements. Further, the lawsuit also alleges that Chemed knowingly submitted false hospice care claims to Medicare for patients who were not terminally ill. The DOJ complaint also claims that Chemed pressured its staff to increase crisis care claims regardless of whether the services were appropriate or actually being provided. On news of the lawsuit, Chemed stock fell
per share, or nearly 17%, to close at
Robbins Arroyo LLP Investigates Failed Internal Controls by Chemed Officers and Directors
Robbins Arroyo LLP's investigation concerns whether certain of Chemed's officers and directors failed to implement adequate internal controls. In addition, Robbins Arroyo LLP is investigating whether these fiduciaries issued false and misleading statements regarding (i) the company's financial condition, and (ii) the implementation and maintenance of internal controls to ensure that Chemed complied with the federal laws.